Pyrazole derivatives of pyridine and naphthyridine as proapoptotic agents in cervical and breast cancer cells.
Female
Humans
Breast Neoplasms
/ drug therapy
Cell Cycle Checkpoints
Apoptosis
Caspases
/ metabolism
Antineoplastic Agents
/ therapeutic use
MCF-7 Cells
Reactive Oxygen Species
/ metabolism
Pyrazoles
/ pharmacology
Pyridines
/ pharmacology
Naphthyridines
/ pharmacology
Cell Proliferation
Cell Line, Tumor
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
01 04 2023
01 04 2023
Historique:
received:
06
10
2022
accepted:
28
03
2023
medline:
4
4
2023
entrez:
3
4
2023
pubmed:
4
4
2023
Statut:
epublish
Résumé
Cancer is one of the leading causes of death worldwide. The increasing prevalence and resistance to chemotherapy is responsible for driving the search of novel molecules to combat this disease. In search of novel compounds with pro-apoptotic potential, pyrazolo-pyridine and pyrazolo-naphthyridine derivatives were investigated against cervical cancer (HeLa) and breast cancer (MCF-7) cells. The anti-proliferative activity was determined through the MTT assay. Potent compounds were then analyzed for their cytotoxic and apoptotic activity through a lactate dehydrogenase assay and fluorescence microscopy after propidium iodide and DAPI staining. Flow cytometry was used to determine cell cycle arrest in treated cells and pro-apoptotic effect was verified through measurement of mitochondrial membrane potential and activation of caspases. Compounds 5j and 5k were found to be most active against HeLa and MCF-7 cells, respectively. G0/G1 cell cycle arrest was observed in treated cancer cells. Morphological features of apoptosis were also confirmed, and an increased oxidative stress indicated the involvement of reactive oxygen species in apoptosis. The compound-DNA interaction studies demonstrated an intercalative mode of binding and the comet assay confirmed the DNA damaging effects. Finally, potent compounds demonstrated a decrease in mitochondrial membrane potential and increased levels of activated caspase-9 and -3/7 confirmed the induction of apoptosis in treated HeLa and MCF-7 cells. The present work concludes that the active compounds 5j and 5k may be used as lead candidates for the development of lead drug molecules against cervical and breast cancer.
Identifiants
pubmed: 37005457
doi: 10.1038/s41598-023-32489-5
pii: 10.1038/s41598-023-32489-5
pmc: PMC10067956
doi:
Substances chimiques
Caspases
EC 3.4.22.-
Antineoplastic Agents
0
Reactive Oxygen Species
0
Pyrazoles
0
Pyridines
0
Naphthyridines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5370Informations de copyright
© 2023. The Author(s).
Références
J Biotechnol. 1992 Sep;25(3):231-43
pubmed: 1368802
Pathophysiology. 2000 Sep;7(3):153-163
pubmed: 10996508
Eur J Med Chem. 2011 Sep;46(9):4676-81
pubmed: 21715067
Front Genet. 2012 Jan 10;2:102
pubmed: 22303396
Bioorg Chem. 2016 Aug;67:43-56
pubmed: 27253830
Cell. 2007 Feb 23;128(4):683-92
pubmed: 17320506
Biotechnol Annu Rev. 2005;11:127-52
pubmed: 16216776
Biochim Biophys Acta. 2016 Dec;1863(12):2977-2992
pubmed: 27646922
Med Chem. 2019;15(8):892-902
pubmed: 30747078
Spectrochim Acta A Mol Biomol Spectrosc. 2012 Aug;94:134-42
pubmed: 22537938
Nat Rev Cancer. 2015 Aug;15(8):473-83
pubmed: 26156638
Circ Res. 2018 Mar 16;122(6):877-902
pubmed: 29700084
Curr Top Med Chem. 2011 Nov;11(22):2714-5
pubmed: 22039874
CA Cancer J Clin. 2016 Jul;66(4):271-89
pubmed: 27253694
Cell. 2004 Jun 11;117(6):773-86
pubmed: 15186778
Science. 2018 Nov 23;362(6417):893-894
pubmed: 30467157
Bioorg Med Chem Lett. 2013 Nov 1;23(21):5893-5
pubmed: 24060486
Assay Drug Dev Technol. 2005 Dec;3(6):675-82
pubmed: 16438662
Oncol Res. 2004;14(9):415-26
pubmed: 15490973
Anticancer Agents Med Chem. 2012 Jul;12(6):653-62
pubmed: 22263796
J Immunol Methods. 1983 Dec 16;65(1-2):55-63
pubmed: 6606682
Eur J Pharmacol. 2018 Aug 5;832:11-24
pubmed: 29763580
Cell Death Dis. 2017 May 25;8(5):e2815
pubmed: 28542135
J Immunol Methods. 1990 Jun 12;130(1):149-51
pubmed: 2358686
Bioorg Chem. 2018 Apr;77:203-214
pubmed: 29367077
Front Pharmacol. 2016 Nov 29;7:457
pubmed: 27965578
J Biomol Struct Dyn. 2020 Jul;38(11):3246-3259
pubmed: 31411114
Acc Chem Res. 2008 Jan;41(1):69-77
pubmed: 17665872
Molecules. 2015 May 12;20(5):8499-520
pubmed: 25985354
Int J Toxicol. 2016 Nov;35(6):672-682
pubmed: 27461214
Molecules. 2014 Dec 12;19(12):20839-63
pubmed: 25514225
Int J Mol Med. 2015 Oct;36(4):1143-50
pubmed: 26239216
Expert Opin Drug Discov. 2009 Nov;4(11):1099-111
pubmed: 23480431
Oncol Rep. 2015 Jul;34(1):288-94
pubmed: 25998412
Nat Commun. 2015 Apr 20;6:6907
pubmed: 25892552
Nat Protoc. 2006;1(1):23-9
pubmed: 17406208
J Med Chem. 2003 Mar 27;46(7):1144-52
pubmed: 12646025
Molecules. 2007 Mar 08;12(3):361-72
pubmed: 17851395
RSC Adv. 2020 Feb 5;10(10):5938-5950
pubmed: 35497456